Literature DB >> 209958

Corticosteroids: clinical pharmacology and therapeutic use.

S L Swartz, R G Dluhy.   

Abstract

The widespread use of corticosteroids in clinical practice emphasises the need for a thorough understanding of their metabolic effects. In general, the actions of corticosteroids on carbohydrate, protein, and lipid metabolism result in increased hepatic capacity for gluconeogenesis and enhanced catabolic actions upon muscle, skin, lymphoid, adipose and connective tissues. Because of the morbidity associated with steroid therapy, the clinician must carefully consider in each case the gains that can reasonably be expected from corticosteroid therapy versus the inevitable undesirable side effects of prolonged therapy. Thus, it is important to remember that the enhanced anti-inflammatory activity of the various synthetic analogues of cortisol is not dissociated from the expected catabolic actions of glucocorticoid hormones. Replacement therapy with physiological doses of cortisol in primary or secondary adrenal insufficiency is intended to simulate the normal daily secretion of cortisol. Short term, high dose suppressive glucocorticoid therapy is indicated in the treatment of medical emergencies such as necrotising vasculitis, status asthmaticus and anaphylactic shock. With improvement of the underlying disorder, the steroid dosage can be rapidly tapered and then discontinued over a 2 to 3 day period. Long term, high dose suppressive therapy is often commonly used to treat certain diseases (see sections 4.7.2 and 4.7.3). In this setting, suppression of the hypothalamic-pituitary-adrenal axis may persist for as long as 9 to 12 months following steroid withdrawal if steroid doses are administered in the supraphysiological range for longer than 2 weeks. In general, higher doses, longer duration of usage, and frequent daily administration are all correlated with the severity of pituitary ACTH suppression. When steroid therapy is to be withdrawn, gradual tapering of the dosage is necessary; the steroid dosage should also be given as a single morning dose if possible. Rapid or total withdrawal of the steroid therapy may be associated with exacerbation of the underlying disease or with a steroid withdrawal syndrome. An additional important point to remember in any withdrawal programme is that the steroid dosage should be appropriately increased for an exacerbation of the underlying disease or for intercurrent major stress. Alternate day therapy is recommended as a steroid maintenance programme for patients requiring high dose glucocorticoid therapy over a prolonged period of time. Thus, it is usually employed to maintain a therapeutic benefit which had previously been extablished by daily steroid treatment. Complications resulting from corticosteroid therapy include: (1) proximal muscle weakness; (2) osteopenia; (3) unmasking of latent diabetes mellitus; (4) sodium retention and/or elevation of mean arterial blood pressure; (5) adverse psychiatric reactions; (6) development of glaucoma; and (7) reactivation of latent infections (such as tuberculosis).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 209958     DOI: 10.2165/00003495-197816030-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  29 in total

1.  Psychotic reactions induced by corticotropin (ACTH) cortisone.

Authors:  G H GLASER
Journal:  Psychosom Med       Date:  1953 Jul-Aug       Impact factor: 4.312

Review 2.  Nonassociation of adrenocorticosteroid therapy and peptic ulcer.

Authors:  H O Conn; B L Blitzer
Journal:  N Engl J Med       Date:  1976-02-26       Impact factor: 91.245

3.  Withdrawal from glucocorticoid therapy.

Authors:  R L Byyny
Journal:  N Engl J Med       Date:  1976-07-01       Impact factor: 91.245

4.  Steroid-induced diabetic ketoacidosis.

Authors:  I A Alavi; B K Sharma; V K Pillay
Journal:  Am J Med Sci       Date:  1971-07       Impact factor: 2.378

Review 5.  Drug spotlight program: systemic corticosteroid therapy: pharmacology and endocrinologic considerations.

Authors:  J C Melby
Journal:  Ann Intern Med       Date:  1974-10       Impact factor: 25.391

6.  Prednisone side-effects and serum-protein levels. A collaborative study.

Authors:  G P Lewis; W J Jusko; L Graves; C W Burke
Journal:  Lancet       Date:  1971-10-09       Impact factor: 79.321

7.  Subcellular mechanisms in the action of adrenal steroids.

Authors:  D Feldman; J W Funder; I S Edelman
Journal:  Am J Med       Date:  1972-11       Impact factor: 4.965

8.  Steroid myopathy. Clinical, histologic and cytologic observations.

Authors:  A K Afifi; R A Bergman; J C Harvey
Journal:  Johns Hopkins Med J       Date:  1968-10

9.  Drugs and gastric damage.

Authors:  A R Cooke
Journal:  Drugs       Date:  1976       Impact factor: 9.546

10.  Glucocorticoid receptors in lymphoma cells in culture: relationship to glucocorticoid killing activity.

Authors:  J D Baxter; A W Harris; G M Tomkins; M Cohn
Journal:  Science       Date:  1971-01-15       Impact factor: 47.728

View more
  33 in total

1.  The role of glucocorticoids and prostaglandin E2 in the recruitment of bone marrow mesenchymal cells to the osteoblastic lineage: positive and negative effects.

Authors:  A Scutt; P Bertram; M Bräutigam
Journal:  Calcif Tissue Int       Date:  1996-09       Impact factor: 4.333

Review 2.  Glucocorticosteroids in football: use and misuse.

Authors:  J Dvorak; N Feddermann; K Grimm
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

3.  Enhanced therapeutic anti-inflammatory effect of betamethasone on topical administration with low-frequency, low-intensity (20 kHz, 100 mW/cm(2)) ultrasound exposure on carrageenan-induced arthritis in a mouse model.

Authors:  Gadi Cohen; Hiba Natsheh; Youhan Sunny; Christopher R Bawiec; Elka Touitou; Melissa A Lerman; Philip Lazarovici; Peter A Lewin
Journal:  Ultrasound Med Biol       Date:  2015-05-21       Impact factor: 2.998

Review 4.  Corticosteroids and glaucoma risk.

Authors:  R C Tripathi; S K Parapuram; B J Tripathi; Y Zhong; K V Chalam
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

5.  Effect of a glucocorticoid on the post-operative course following experimental orthopaedic surgery in dogs.

Authors:  S W Mbugua; L A Skoglund; P Skjelbred; P Løkken
Journal:  Acta Vet Scand       Date:  1988       Impact factor: 1.695

Review 6.  Toward optimal use of corticosteroids in ulcerative colitis and Crohn's disease.

Authors:  J E Lennard-Jones
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

7.  Treatment Satisfaction, Product Perception, and Quality of Life in Plaque Psoriasis Patients Using Betamethasone Dipropionate Spray 0.05.

Authors:  Joseph F Fowler; James Q Del Rosso; Refika I Pakunlu; Srinivas Sidgiddi
Journal:  J Clin Aesthet Dermatol       Date:  2017-11-01

8.  Post-operative pain and inflammatory reaction reduced by injection of a corticosteroid. A controlled trial in bilateral oral surgery.

Authors:  P Skjelbred; P Løkken
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test.

Authors:  Z Lević; D Micić; J Nikolić; N Stojisavljević; D Sokić; S Janković; A Kendereski; M Mavra
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

10.  Absorption of prednisolone in patients with Crohn's disease.

Authors:  J A Shaffer; S E Williams; L A Turnberg; J B Houston; M Rowland
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.